Literature DB >> 28289191

Cathepsin S is the major activator of the psoriasis-associated proinflammatory cytokine IL-36γ.

Joseph S Ainscough1, Tom Macleod1, Dennis McGonagle2,3, Rosella Brakefield1, Jens M Baron4, Ade Alase2, Miriam Wittmann5,3, Martin Stacey6.   

Abstract

The proinflammatory cytokine IL-36γ is highly expressed in epithelial cells and is a pivotal mediator of epithelial inflammation. In particular, IL-36γ is strongly associated with the inflammatory skin disease psoriasis. As with other IL-1 cytokines, IL-36γ is expressed as an inactive precursor and must be processed by specific proteases to become bioactive. Our aim therefore was to identify protease/s capable of IL-36γ activation and explore the importance of this activation in psoriasis. Using a keratinocyte-based activity assay in conjunction with small-molecule inhibitors and siRNA gene silencing, cathepsin S was identified as the major IL-36γ-activating protease expressed by epithelial cells. Interestingly, cathepsin S activity was strongly up-regulated in samples extracted from psoriasis patients relative to healthy controls. In addition, IL-36γ-Ser18, identified as the main product of cathepsin S-dependent IL-36γ cleavage, induced psoriasiform changes in human skin-equivalent models. Together, these data provide important mechanistic insights into the activation of IL-36γ and highlight that cathepsin S-mediated activation of IL-36γ may be important in the development of numerous IL-36γ-driven pathologies, in addition to psoriasis.

Entities:  

Keywords:  IL-1; IL-36; cytokine; inflammation; psoriasis

Mesh:

Substances:

Year:  2017        PMID: 28289191      PMCID: PMC5380102          DOI: 10.1073/pnas.1620954114

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  49 in total

Review 1.  IL-1 pathways in inflammation and human diseases.

Authors:  Cem Gabay; Céline Lamacchia; Gaby Palmer
Journal:  Nat Rev Rheumatol       Date:  2010-02-23       Impact factor: 20.543

Review 2.  The interleukin-1 family: back to the future.

Authors:  Cecilia Garlanda; Charles A Dinarello; Alberto Mantovani
Journal:  Immunity       Date:  2013-12-12       Impact factor: 31.745

3.  Cutaneous reactions to recombinant cytokine therapy.

Authors:  M Papini; P L Bruni
Journal:  J Am Acad Dermatol       Date:  1996-12       Impact factor: 11.527

4.  IL-36 signaling amplifies Th1 responses by enhancing proliferation and Th1 polarization of naive CD4+ T cells.

Authors:  Solenne Vigne; Gaby Palmer; Praxedis Martin; Céline Lamacchia; Deborah Strebel; Emiliana Rodriguez; Maria L Olleros; Dominique Vesin; Irene Garcia; Francesca Ronchi; Federica Sallusto; John E Sims; Cem Gabay
Journal:  Blood       Date:  2012-09-11       Impact factor: 22.113

5.  Psoriasiform dermatitis is driven by IL-36-mediated DC-keratinocyte crosstalk.

Authors:  Luigi Tortola; Esther Rosenwald; Brian Abel; Hal Blumberg; Matthias Schäfer; Anthony J Coyle; Jean-Christoph Renauld; Sabine Werner; Jan Kisielow; Manfred Kopf
Journal:  J Clin Invest       Date:  2012-10-15       Impact factor: 14.808

Review 6.  Current and emerging systemic treatment strategies for psoriasis.

Authors:  Philip M Laws; Helen S Young
Journal:  Drugs       Date:  2012-10-01       Impact factor: 9.546

7.  IL-36γ (IL-1F9) is a biomarker for psoriasis skin lesions.

Authors:  Angelo Massimiliano D'Erme; Dagmar Wilsmann-Theis; Julia Wagenpfeil; Michael Hölzel; Sandra Ferring-Schmitt; Sonja Sternberg; Miriam Wittmann; Bettina Peters; Andreas Bosio; Thomas Bieber; Joerg Wenzel
Journal:  J Invest Dermatol       Date:  2014-12-19       Impact factor: 8.551

8.  IL-1F5, -F6, -F8, and -F9: a novel IL-1 family signaling system that is active in psoriasis and promotes keratinocyte antimicrobial peptide expression.

Authors:  Andrew Johnston; Xianying Xing; Andrew M Guzman; MaryBeth Riblett; Candace M Loyd; Nicole L Ward; Christian Wohn; Errol P Prens; Frank Wang; Lisa E Maier; Sewon Kang; John J Voorhees; James T Elder; Johann E Gudjonsson
Journal:  J Immunol       Date:  2011-01-17       Impact factor: 5.422

9.  Distinct expression of interleukin (IL)-36α, β and γ, their antagonist IL-36Ra and IL-38 in psoriasis, rheumatoid arthritis and Crohn's disease.

Authors:  M-A Boutet; G Bart; M Penhoat; J Amiaud; B Brulin; C Charrier; F Morel; J-C Lecron; M Rolli-Derkinderen; A Bourreille; S Vigne; C Gabay; G Palmer; B Le Goff; F Blanchard
Journal:  Clin Exp Immunol       Date:  2016-02-22       Impact factor: 4.330

Review 10.  Understanding the mechanism of IL-1β secretion.

Authors:  Gloria Lopez-Castejon; David Brough
Journal:  Cytokine Growth Factor Rev       Date:  2011-10-22       Impact factor: 7.638

View more
  50 in total

Review 1.  Psoriasis: a mixed autoimmune and autoinflammatory disease.

Authors:  Yun Liang; Mrinal K Sarkar; Lam C Tsoi; Johann E Gudjonsson
Journal:  Curr Opin Immunol       Date:  2017-07-22       Impact factor: 7.486

2.  IL-36γ induces a transient HSV-2 resistant environment that protects against genital disease and pathogenesis.

Authors:  Jameson K Gardner; Melissa M Herbst-Kralovetz
Journal:  Cytokine       Date:  2018-08-15       Impact factor: 3.861

3.  Differential effects of specific cathepsin S inhibition in biocompartments from patients with primary Sjögren syndrome.

Authors:  Patrick Hargreaves; Douglas Daoudlarian; Michel Theron; Fabrice A Kolb; Marianne Manchester Young; Bernhard Reis; Andre Tiaden; Bettina Bannert; Diego Kyburz; Tobias Manigold
Journal:  Arthritis Res Ther       Date:  2019-07-18       Impact factor: 5.156

Review 4.  Generalized Pustular Psoriasis in Pregnancy: Current and Future Treatments.

Authors:  Mariko Seishima; Kento Fujii; Yoko Mizutani
Journal:  Am J Clin Dermatol       Date:  2022-06-15       Impact factor: 6.233

5.  IL-36 and IL-1/IL-17 Drive Immunity to Oral Candidiasis via Parallel Mechanisms.

Authors:  Akash H Verma; Hanna Zafar; Nicole O Ponde; Olivia W Hepworth; Diksha Sihra; Felix E Y Aggor; Joseph S Ainscough; Jemima Ho; Jonathan P Richardson; Bianca M Coleman; Bernhard Hube; Martin Stacey; Mandy J McGeachy; Julian R Naglik; Sarah L Gaffen; David L Moyes
Journal:  J Immunol       Date:  2018-06-11       Impact factor: 5.422

6.  Performance evaluation of molecular docking and free energy calculations protocols using the D3R Grand Challenge 4 dataset.

Authors:  Eddy Elisée; Vytautas Gapsys; Nawel Mele; Ludovic Chaput; Edithe Selwa; Bert L de Groot; Bogdan I Iorga
Journal:  J Comput Aided Mol Des       Date:  2019-11-01       Impact factor: 3.686

Review 7.  Interleukin-36: Structure, Signaling and Function.

Authors:  Li Zhou; Viktor Todorovic
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 8.  IL-36 in chronic inflammation and fibrosis - bridging the gap?

Authors:  Michael Elias; Shuai Zhao; Hongnga T Le; Jie Wang; Markus F Neurath; Clemens Neufert; Claudio Fiocchi; Florian Rieder
Journal:  J Clin Invest       Date:  2021-01-19       Impact factor: 14.808

Review 9.  "Autoinflammatory psoriasis"-genetics and biology of pustular psoriasis.

Authors:  Ranjitha Uppala; Lam C Tsoi; Paul W Harms; Bo Wang; Allison C Billi; Emanual Maverakis; J Michelle Kahlenberg; Nicole L Ward; Johann E Gudjonsson
Journal:  Cell Mol Immunol       Date:  2020-08-19       Impact factor: 11.530

Review 10.  The Role of IL-36 in Infectious Diseases: Potential Target for COVID-19?

Authors:  Xiaofang Wang; Panpan Yi; Yuejin Liang
Journal:  Front Immunol       Date:  2021-05-13       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.